Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: FASEB J. 2023 Nov;37(11):e23251. doi: 10.1096/fj.202301122RR

Figure 3. Whole body silencing Lpcat3 expression improves HFD-induced obesity and insulin resistance.

Figure 3.

A. Expression of Lpcat3 in different tissues of chow diet-fed C57BL/6 mice subcutaneously injected with control and Lpcat3 targeting ASOs (n=5–8/group).

B. Growth curve of C57BL/6 mice fed HFD for 8 weeks followed by subcutaneous injection with control (Con-ASO) or Lpcat3 targeting ASO (Lpcat3-ASO) (n=12/group).

C and F. Mouse body weight when GTT and ITT were performed.

D-E and G-H. GTT, ITT and area under the curve (AUC) analysis in HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO (n=11–12/group).

I-K. Fasting blood glucose (I), serum insulin levels (J) and HOMA-IR (K) of HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO.

L-N. Final body weight (L), eWAT weight (M) and sWAT weight (N) of HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO.

O. Food consumption of HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO.

Data are presented as means ± SEM. Statistical analysis was performed with Student’s t test (A-C, E-F, H-O), and two-way ANOVA (D and G). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.